Experience from two HIV-infected patients with ALK-rearranged NSCLC proved that these patients had good responses to first as well as to second generation ALK-inhibitors, but both patients required a preventive modification of HAART regimens in order to avoid DDIs: ALK-TKIs are metabolized by CYP3A4, so a co-administration of CYP inhibitors can cause QT prolongation [35]. This evidence concerns the gene ALK and non-small cell lung carcinoma.